The FDA has approved aprepitant (Emend, Merck), in combination with other antiemetics, for the prevention of nausea and vomiting in patients undergoing moderately emetogenic chemotherapy, according to ...

Aprepitant is associated with improved survival outcomes in early-stage breast cancer, particularly in triple-negative cases, showing significant DDFS and BCSS improvements. The study analyzed 13,811 ...

Learn everything you need to know about Aprepitant-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer This is the first study in which ...

Review the side-effects of Aprepitant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 ...

Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving 5-day cisplatin-containing ...

Aprepitant (Emend, Merck & Co.), which is already approved for use in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV), has now been shown to also be effective in children ...

BOSTON — Aprepitant (Emend, Merck & Co, Inc), a drug approved for chemotherapy-induced nausea and vomiting, has shown promise as an antitussive agent in a small trial of patients with lung cancer.

We report on three patients with the Sézary syndrome in whom pruritus was the main symptom and could not be controlled with conventional therapy. All three patients presented with erythroderma and ...